Medpace Holdings Inc. (MEDP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Medpace Holdings Inc. (MEDP:NASDAQ), powered by AI.

Current Price
$461.60
P/E Ratio
29.5
Market Cap
13.3B
Sector
Healthcare
What is the Medpace Holdings Inc. stock price forecast?

Medpace Holdings Inc. is currently trading at $461.60. View real-time AI analysis on Alpha Lenz.

What is Medpace Holdings Inc. insider trading activity?

View the latest insider trading data for Medpace Holdings Inc. on Alpha Lenz.

What is Medpace Holdings Inc.'s P/E ratio?

Medpace Holdings Inc.'s P/E ratio is 29.5.

Medpace Holdings Inc.

NASDAQ · MEDP
$461.60-5.90(-1.26%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Medpace Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Medpace Holdings Inc. trades at a P/E of 29.5 (premium valuation) with strong ROE of 70.2%. 3Y revenue CAGR of 20.1% highlights clear growth momentum.

Ask for details

Company Overview

Medpace Holdings Inc. is a prominent entity in the clinical contract research organization sector, providing comprehensive services essential for the development and commercialization of pharmaceutical products. The company's primary function is to assist biotechnology, pharmaceutical, and medical device companies by managing deep and complex activities essential for conducting clinical trials. Medpace is renowned for its full-service approach, facilitating everything from preclinical studies through to post-marketing approval, ensuring compliance and efficacy at each stage of the drug development process. Operating internationally, Medpace impacts various therapeutic areas, ranging from oncology to cardiovascular and metabolic diseases, among others. Its ability to offer globally standardized services with a focus on efficiency and quality makes it a valuable partner in the increasingly complex and regulated world of drug development. In the financial market, Medpace plays a crucial role by accelerating the entry of new therapies and innovations, aiding in the improvement of public health outcomes, and supporting the continuous growth and dynamism of the life sciences industry. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace aligns scientific expertise with rigorous process management to drive success for its clients.

CEODr. August James Troendle M.D.
SectorHealthcare
IndustryDiagnostics & Research
Employees6,000

Company Statistics

FY 2025

Profile

$13.32BMarket Cap
$2.53BRevenue
0.00Shares Out
6,000Employees

Margins

30.06%Gross
22.56%EBITDA
21.14%Operating
21.44%Pre-Tax
17.83%Net

Valuation

29.52P/E
29.00P/B
5.26EV/Sales
22.66EV/EBITDA
19.53P/FCF

Growth (CAGR)

20.12%Rev 3Yr
22.27%Rev 5Yr
24.28%Op Inc 3Yr
26.21%Op Inc 5Yr
22.51%Net Inc 3Yr
25.42%Net Inc 5Yr

Returns

22.13%ROA
70.23%ROE
26.25%ROIC

Financial Health

$497.05MCash & Cash Equivalents
$1.02BNet Debt
330.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Medpace Holdings Inc. (ticker: MEDP) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 6,000 employees. Market cap is $13.3B.

The current price is $461.6 with a P/E ratio of 29.52x and P/B of 29x.

ROE is 70.23% and operating margin is 21.14%. Annual revenue is $2.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Medpace Holdings Inc. (MEDP) Stock Forecast 2026 $461.60 — Price, Financials & Analyst Targets | Alpha Lenz